Revumenib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 110 mg, 160 mg
Reference Brands: Revuforj (USA)
Category:
Oncology Cancer Care
Revumenib is available in Tablets
and strengths such as 25 mg, 110 mg, 160 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Revumenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Revumenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Revumenib is an oral targeted anticancer medication used for the treatment of acute leukemias with lysine methyltransferase 2A (KMT2A) gene rearrangements and is marketed under the brand name Revuforj. It is specifically indicated for patients whose cancers harbor KMT2A translocations, which are known to drive aggressive leukemia progression.
Revumenib works as a menin inhibitor, disrupting the interaction between the menin protein and KMT2A (also called MLL). This interaction is critical for the survival and proliferation of leukemia cells in patients with KMT2A-rearranged acute leukemia. By blocking this pathway, revumenib helps to slow or halt cancer cell growth, providing a precision oncology approach for patients with genetically defined leukemias.
Administered orally as a film-coated tablet, revumenib offers a convenient dosing option while targeting the molecular drivers of the disease. It is generally used under medical supervision, with prior genetic testing to confirm the presence of KMT2A gene rearrangements. Revumenib represents an important therapeutic option for patients with difficult-to-treat, relapsed, or refractory acute leukemias driven by specific genetic abnormalities.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing